Skip to main content

Table 2 Baseline patient characteristics in phase II study

From: Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response

Characteristic No. of patients %
No. of patients 36 100
Gender   
Male 31 86.1
Female 5 13.9
Age, years   
Median 56  
Range 26-77  
ECOG performance status   
0 24 66.7
1 12 33.3
Hepatitis status   
Hepatitis B 29 80.5
Hepatitis C 1 2.8
Non-B non-C 6 16.7
Baseline AFP > 10 μg/l   
Yes 25 69.4
No 11 30.6
Tumour Burden   
BCLC Stage B 28  
  BCLC stage C 8  
  Macroscopic vascular invasion 24 66.7
Extrahepatic disease 21 58.3
Prior therapy for HCC of any forms 29 80.6
Blood parameters (median, range):   
Total bilirubin 16 (5–34) umol/l  
Albumin 39. (32–48) g/l  
Alanine transaminase 40 (18–140) iu/l  
Alkaline phosphatase 108 (52–434) iu/l  
AFP 82 (1–118712) ug/l  
INR 1.06 (0.89-1.26)  
Creatinine 82 (44–136) umol/l  
Glucose 5.4 (4.0-8.5) mmol/l  
Triglyceride 0.9 (0.5-2.0) mmol/l  
LDL cholesterol 2.65 (1.6-7.3) mmol/l  
HDL cholesterol 1.15 (0.7-2.5) mmol/l  
Total cholesterol 4.45 (3.0-8.9) mmol/l  
Prior systemic therapy   
1 line 11 30.5
2 lines 1 2.8
3 lines 1 2.8
Prior local +/− regional therapy   
Surgery 23 63.9
*Local ablation 4 11.0
Transarterial therapy 20 55.5
  1. *2 had radiofrequency ablation and 2 had percutaneous ethanol injection.